Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cockroach Nasal Allergen Challenge in Asthma
NCT02710136Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of german cockroach allergenic extract in asthma and cockroach allergy, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Cumulative Proportion of Participants Meeting Either a Total Nasal Symptom Score (TNSS) Threshold or Sneezing Score Threshold During the Cockroach Allergen (CA) Nasal Allergen Challenge (NAC). Started Feb 2016; status: completed.
02
Drugs
german cockroach allergenic extract
03
Conditions
asthmacockroach allergy
Beyond the preview
Go deeper on NCT02710136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02710136.